Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer

[1]  B. Bastian,et al.  Assessment of Copy Number Status of Chromosomes 6 and 11 by FISH Provides Independent Prognostic Information in Primary Melanoma , 2011, The American journal of surgical pathology.

[2]  N. Rouas-Freiss,et al.  Recent advances on the non-classical major histocompatibility complex class I HLA-G molecule. , 2010, Tissue antigens.

[3]  N. Rouas-Freiss,et al.  Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of high-grade histology. , 2009, Human immunology.

[4]  Hans W. Nijman,et al.  Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer , 2008, Cancer Immunology, Immunotherapy.

[5]  B. Seliger,et al.  The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma , 2009, Cancer Immunology, Immunotherapy.

[6]  R. Berkowitz,et al.  Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer , 2008, Clinical Cancer Research.

[7]  T. Daemen,et al.  Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation. , 2008, Gynecologic oncology.

[8]  Soldano Ferrone,et al.  HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma , 2008, Clinical Cancer Research.

[9]  B. Seliger,et al.  Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer. , 2007, Tissue antigens.

[10]  E. Jordanova,et al.  Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma , 2007, Cancer Immunology, Immunotherapy.

[11]  P. Rolland,et al.  Human Leukocyte Antigen Class I Antigen Expression Is an Independent Prognostic Factor in Ovarian Cancer , 2007, Clinical Cancer Research.

[12]  H. Yamamoto,et al.  Characterization of the immune escape phenotype of human gastric cancers with and without high‐frequency microsatellite instability , 2007, The Journal of pathology.

[13]  T. Dalianis,et al.  Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. , 2006, Gynecologic oncology.

[14]  R. Agarwal,et al.  Novel therapeutic agents in ovarian cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[16]  P. Maes,et al.  Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? , 2004, Blood.

[17]  B. Seliger,et al.  Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? , 2004, The Journal of urology.

[18]  Brigitte M. Ronnett,et al.  The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[19]  P. Maisonneuve,et al.  Carcinoma of the ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[20]  F. Dammacco,et al.  β2-Microglobulin-Free HLA Class I Heavy Chain Epitope Mimicry by Monoclonal Antibody HC-10-Specific Peptide1 , 2003, The Journal of Immunology.

[21]  Hein Putter,et al.  Down-Regulation of HLA-A Expression Correlates with a Better Prognosis in Colorectal Cancer Patients , 2002, Laboratory Investigation.

[22]  Jeffrey E. Lee,et al.  Presence of the human leukocyte antigen class II geneDRB1*1101 predicts interferon γ levels and disease recurrence in melanoma patients , 2002, Annals of Surgical Oncology.

[23]  V. Sondak,et al.  Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Maier,et al.  Human Leukocyte Antigens and Prognosis in Patients With Head and Neck Cancer: Results of a Prospective Follow‐up Study , 2002, The Laryngoscope.

[25]  In-Kyung Kim,et al.  Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers , 2002, Experimental & Molecular Medicine.

[26]  Christian Lindig,et al.  HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer. , 2001, Cancer biotherapy & radiopharmaceuticals.

[27]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[28]  K. Yasumoto,et al.  Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. , 2001, Lung cancer.

[29]  H. Ngan,et al.  FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[30]  F. Vela,et al.  Cervical carcinoma: human papillomavirus infection and HLA-associated risk factors in the Spanish population. , 1998, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[31]  G. Coukos,et al.  CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER: NEW MOLECULAR PERSPECTIVES , 1998, Obstetrics and gynecology.

[32]  R. Elashoff,et al.  Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Ploegh,et al.  Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. , 1998, Molecular immunology.

[34]  N. Iizuka,et al.  Phenotype Frequency of Human Leukocyte Antigens in Japanese Patients with Renal Cell Carcinoma who Responded to Interferon‐α Treatment , 1996, International journal of urology : official journal of the Japanese Urological Association.

[35]  F. Garrido.  HLA and cancer. , 1996, Tissue antigens.

[36]  D. F. Roberts,et al.  The History and Geography of Human Genes , 1996 .

[37]  E. Adams,et al.  The Origins of HLA‐A,B,C Polymorphism , 1995, Immunological reviews.

[38]  A. Herbst.  The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. , 1994, American journal of obstetrics and gynecology.

[39]  F. Marincola,et al.  HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. , 1992, Cancer research.

[40]  S. Groshen,et al.  Association of HLA phenotype with response to active specific immunotherapy of melanoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  H. Ploegh,et al.  HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. , 1990, International immunology.

[42]  H. Ploegh,et al.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. , 1986, Journal of immunology.

[43]  J. Whelan,et al.  Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. , 1983, Journal of immunology.

[44]  A. Dellon,et al.  Prolonged disease‐free survival in bronchogenic carcinoma associated with HLA‐Aw19 and HLA‐B5: A two‐year prospective study , 1977, Cancer.

[45]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[46]  P. Pisa,et al.  Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates , 2004, Medical oncology.

[47]  F. Garrido,et al.  Analysis of HLA expression in human tumor tissues , 2002, Cancer Immunology, Immunotherapy.

[48]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[49]  H. Kantarjian,et al.  Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia , 1998, Leukemia.

[50]  J. Blay,et al.  Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. , 1997, British Journal of Cancer.

[51]  C A SALVATORE,et al.  [Carcinoma of the ovary]. , 1960, Anais brasileiros de ginecologia.